Details for Patent: 12,492,167

Which drugs does patent 12,492,167 protect, and when does it expire?

Patent 12,492,167 protects DAYBUE STIX and DAYBUE and is included in two NDAs.

Protection for DAYBUE STIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirteen patent family members in twelve countries.

Summary for Patent: 12,492,167

Title:	Crystalline forms of trofinetide
Abstract:	This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.
Inventor(s):	Matthew Peterson, Marlon Carlos, Martin Bernard Catherine Bousmanne, Cecilia Betti, David T. JONAITIS, Lisa M. McCracken, Lisa M. GROVE
Assignee:	Acadia Pharmaceuticals Inc
Application Number:	US18/491,057
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Device;

Drugs Protected by US Patent 12,492,167

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-001	Dec 11, 2025		RX	Yes	Yes					Y
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-002	Dec 11, 2025		RX	Yes	Yes					Y
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-003	Dec 11, 2025		RX	Yes	Yes					Y

International Family Members for US Patent 12,492,167

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2022309740
Brazil	112023026559
Canada	3224298